ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis

Elio Carmona1, Alyssa Rosek2, Neha Khanna2, Dinesh Khanna3, Amr Sawalha4 and Pei-Suen Tsou3, 1Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 3University of Michigan, Ann Arbor, MI, 4University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2025

Keywords: Angiogenesis, Scleroderma, Systemic sclerosis, transcription factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly reduced in diffuse cutaneous (dc) SSc dermal endothelial cells (ECs) compared to those from healthy individuals. We also observed an increase in the chromatin binding of ETV2, a key transcription factor in the ETS family, within dcSSc ECs. ETV2 is crucial for both hematopoietic and EC function and has been implicated in reprogramming non-ECs to an endothelial phenotype. Its deficiency results in developmental failure of blood vessels in embryos. Here, we explore the impact of ETV2 dysregulation on EC dysfunction in SSc.

Methods: ECs were isolated from skin biopsies of healthy subjects and dcSSc patients. We evaluated ETV2 expression using qPCR, Western blot, and immunofluorescence. ETV2 was overexpressed in ECs via viral transduction, and its expression was also profiled in scRNA-seq data from 18 healthy individuals and 23 dcSSc patients. We assessed functional outcomes like proliferation and angiogenesis. To pinpoint genes influenced by ETV2 in dcSSc ECs, CUT&RUN-seq and bulk RNA-seq were utilized. Statistical significance was set at P < 0.05.

Results: Despite low baseline levels, ETV2 was markedly upregulated in dcSSc ECs compared to controls. scRNA-seq analysis showed increased ETV2 expression in capillary and venular ECs in SSc skin. ETV2 overexpression in dcSSc ECs significantly boosted EC proliferation (n=4 patient lines, p < 0.01) and angiogenic activity, evidenced by increased tube and node formation on Matrigel (n=4 patient lines, p < 0.05). Relative to healthy ECs, dcSSc ECs showed decreased CDH5 and increased COL1A1 and CDKN1A expression, indicative of an endothelial-to-mesenchymal transition phenotype and elevated cellular senescence. ETV2 overexpression elevated EC marker CDH5 (1.385 ± 0.17, p < 0.05 vs. control, fold change) and diminished fibrotic marker COL1A1 (0.680 ± 0.147, p < 0.05 vs. control, fold change) and senescence marker CDKN1A (0.719 ± 0.175, p < 0.05 vs. control, fold change). Through CUT&RUN-seq and bulk RNA-seq, we identified specific genes and pathways significantly regulated by ETV2 in dcSSc ECs.

Conclusion: This study highlights the significant impact of ETV2 in modifying EC function in dcSSc. Upregulation of ETV2 is associated with increased cell proliferation and angiogenesis, which may contribute to disease progression. Changes in gene expression following ETV2 overexpression suggest its potential to reverse endothelial-to-mesenchymal transition and reduce senescence. Further investigation into ETV2-regulated pathways could provide valuable insights into SSc vasculopathy. 1. Tsou et al. Genome-Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin. Arthritis Rheumatol. 2021 Aug;73(8):1501-1513.


Disclosures: E. Carmona: None; A. Rosek: None; N. Khanna: None; D. Khanna: Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Novartis, 2, UCB, 2, Zura Bio, 2; A. Sawalha: None; P. Tsou: None.

To cite this abstract in AMA style:

Carmona E, Rosek A, Khanna N, Khanna D, Sawalha A, Tsou P. Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/examining-the-impact-of-etv2-on-altered-endothelial-phenotype-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examining-the-impact-of-etv2-on-altered-endothelial-phenotype-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology